The clinical efficacy and safety of sildenafil in premature ejaculate: a meta-analysis

This study aims to assess the efficacy and safety of sildenafil therapy compared with other agents in patients with premature ejaculation (PE) but without erectile dysfunction (ED). Systematically literature search was performed using PubMed, EMBASE, Medline, Science Direct/Elsevier, CNKI, and the Cochrane Library. The mean difference (MD) or relative risk (RR) and 95% confidence intervals (CI) were used to assess the efficacy and safety of sildenafil treatment compared with other agents in men with PE. 13 studies, including 506 cases and 506 controls, were identified. The results suggested that when compared with other agents, sildenafil had a better effect on intravaginal ejaculation latency time (IELT) (MD: 1.56, 95% CI: 1.23-1.90), number of coitus per week (MD: 0.78, 95% CI: 0.72-0.84) and overall coitus satisfaction rate (RR: 1.32, 95% CI: 1.17-1.48), However, a higher but acceptable rate of adverse events was found in the patients treated with sildenafil (RR: 2.13, 95% CI: 1.28-3.53). The present study shows that sildenafil was more effective in prolonging IELT, increasing the number of coitus per week and increasing the overall coitus satisfaction rate with an acceptable rate of side effects than other treatment agents.